MLTX Stock Analysis: MoonLake Immunotherapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.583m USD | 12M Return: -59.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 22.2M
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing Sonelokimab, a tri-specific Nanobody designed to inhibit IL-17A and IL-17F, for inflammatory skin and joint diseases. Its pipeline targets hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland, with shares listed on NASDAQ under the ticker MLTX.
As a clinical-stage biotech, MoonLake has not yet commercialized a product and its value is largely tied to the progression of its lead candidate through clinical trials, with future revenue contingent on regulatory approval or licensing deals. Nanobodies are small antibody fragments derived from camelid heavy-chain-only antibodies, offering potential advantages in tissue penetration and manufacturing compared to conventional monoclonal antibodies used in the same inflammatory disease space.
- Sonelokimab Phase 3 hidradenitis suppurativa data readout
- Cash burn widens as pivotal trials advance
- Competition from UCBs Bimzelx pressures HS market positioning
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.58 > 0.02 and ΔFCF/TA -31.05 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.56 > 3% & CFO -224.2m > Net Income -257.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (71.3m) vs 12m ago 12.71% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.02%; Δ -0.02% > 0%) |
| Interest Coverage Ratio: -26.20 > 6 (EBIT TTM -248.9m / Interest Expense TTM 9.50m) |
| A: 0.88 (Total Current Assets 396.6m - Total Current Liabilities 46.1m) / Total Assets 400.4m |
| B: -1.33 (Retained Earnings -532.6m / Total Assets 400.4m) |
| C: -0.55 (EBIT TTM -248.9m / Avg Total Assets 455.8m) |
| D: 1.74 (Book Value of Equity 254.0m / Total Liabilities 146.3m) |
| Altman-Z'' = -0.44 = B |
As of July 08, 2026, the stock is trading at USD 19.15 with a total of 1,386,472 shares traded. Over the past week, the price has changed by -3.82%, over one month by +6.39%, over three months by +12.12% and over the past year by -59.68%.
Current recommended Stop Loss: 16.50 (which is 13.8% or 2.5 ATR below the current price).
MoonLake Immunotherapeutics has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy MLTX.
- StrongBuy: 12
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 28 | 46.2% |
P/B = 6.2912
Revenue TTM = 0.0 USD
EBIT TTM = -248.9m USD
EBITDA TTM = -245.8m USD
Long Term Debt = 99.0m USD (from longTermDebt, last quarter)
Short Term Debt = 920k USD (from shortTermDebt, last quarter)
Debt = 102.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.78m
Net Debt = -252.2m USD (calculated: Debt 102.6m - CCE 354.8m)
Enterprise Value = 1.33b USD (1.58b + Debt 102.6m - CCE 354.8m)
Interest Coverage Ratio = -26.20 (Ebit TTM -248.9m / Interest Expense TTM 9.50m)
EV/FCF = -5.73x (Enterprise Value 1.33b / FCF TTM -232.4m)
FCF Yield = -17.46% (FCF TTM -232.4m / Enterprise Value 1.33b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.08m) / Revenue TTM)
Tobins Q-Ratio = 3.33 (Enterprise Value 1.33b / Total Assets 400.4m)
Interest Expense / Debt = 9.26% (Interest Expense 9.50m / Debt 102.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -196.6m (EBIT -248.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.71 (Total Current Assets 396.6m / Total Current Liabilities 69.5m)
Debt / Equity = 0.40 (Debt 102.6m / totalStockholderEquity, last quarter 254.0m)
Debt / EBITDA = 1.03 (negative EBITDA) (Net Debt -252.2m / EBITDA -245.8m)
Debt / FCF = 1.09 (negative FCF - burning cash) (Net Debt -252.2m / FCF TTM -232.4m)
Total Stockholder Equity = 300.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -56.40% (Net Income -257.1m / Total Assets 400.4m)
RoE = -85.61% (Net Income TTM -257.1m / Total Stockholder Equity 300.3m)
RoCE = -62.33% (EBIT -248.9m / Capital Employed (Equity 300.3m + L.T.Debt 99.0m))
RoIC = -55.36% (negative operating profit) (NOPAT -196.6m / Invested Capital 355.2m)
WACC = 7.44% (E(1.58b)/V(1.69b) * Re(7.45%) + D(102.6m)/V(1.69b) * Rd(9.26%) * (1-Tc(0.21)))
Discount Rate = 7.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 8.02%
[DCF] Fair Price = unknown (Cash Flow -232.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.54 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.90 | Chg30d=+7.61% | Revisions=-29% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.92 | Chg30d=+10.04% | Revisions=-17% | Analysts=8
EPS current Year (2026-12-31): EPS=-3.84 | Chg30d=+2.45% | Revisions=-22% | GrowthEPS=-8.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.43 | Chg30d=+0.47% | Revisions=+30% | GrowthEPS=+10.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -9% (up=9, down=11)